Clinical Trails

Results from the phase 3 PSMAddition trial showed that adding lutetium Lu 177 vipivotide tetraxetan (Pluvicto) to androgen-deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI) improved prostate-specific antigen (PSA) responses in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The randomized phase 3 study included 1,144 men with PSMA-positive mHSPC. Patients received either Pluvicto […]

A Phase 2 randomized study found that giving two preoperative doses of intravesical mitomycin-C before TURBT significantly reduced recurrence and progression in patients with non–muscle-invasive bladder cancer. The strategy is based on the idea that tumor manipulation during surgery can release cancer cells that later reimplant in the bladder. By administering chemotherapy before surgery, while

Interim results showed that detalimogene voraplasmid, a non-viral intravesical gene therapy, demonstrated encouraging activity and safety in patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer who had already received extensive prior treatment. Among 125 evaluable patients, 54% achieved a complete response at some point during treatment, and most responses were seen by the first two-month assessment.

High-level results from the phase 3 VOLGA trial show that combining durvalumab (Imfinzi) with enfortumab vedotin (Padcev) before surgery significantly improves survival for patients with muscle-invasive bladder cancer who cannot receive or choose not to receive cisplatin chemotherapy. The treatment improved both event-free survival and overall survival compared with surgery alone. Another treatment group using

A Phase 1/2 study found that combining Belantamab mafodotin with the KRd regimen (carfilzomib, lenalidomide, and dexamethasone) produced strong and durable responses in patients with relapsed or refractory multiple myeloma. Researchers tested a new dosing schedule for belamaf, giving the drug every eight weeks instead of every three weeks to reduce eye-related side effects while

Interim results from the Phase 2 HexAgon study showed that adding the OX40 agonist INBRX-106 to Keytruda improved outcomes for patients with advanced head and neck squamous cell carcinoma (HNSCC). The combination treatment achieved a confirmed overall response rate of 44%, compared with 21.4% for Keytruda alone. Three patients receiving the combination therapy had a

A Phase 1 study found that the new radioligand therapy [177Lu]Lu-D-Dan-Phe-PSMA is safe and effective for patients with metastatic castration-resistant prostate cancer (mCRPC). The treatment was designed to stay in the body and tumors longer than current therapies such as Pluvicto, allowing it to deliver more radiation directly to cancer cells. In the highest dose

MimiVax Inc. and Roswell Park Comprehensive Cancer Center have started a Phase 2 clinical trial to test the cancer vaccine SurVaxM in patients with worsening neuroendocrine tumors (NETs). The study will compare SurVaxM plus the chemotherapy drug temozolomide with temozolomide alone. SurVaxM is designed to help the immune system attack survivin, a protein linked to

Updated Phase 2 trial results showed that combining rintatolimod with Pembrolizumab and cisplatin may greatly improve outcomes for patients with platinum-sensitive recurrent ovarian cancer. Among 24 evaluable patients, the treatment achieved a 50% objective response rate, including 5 complete responses. This was much higher than the response rate previously seen with pembrolizumab alone. The clinical benefit

Updated interim results from the Phase 2 LEGEND trial show that detalimogene voraplasmid may be an effective treatment for patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer (NMIBC). The therapy is delivered directly into the bladder to trigger a local immune response against tumors. The study showed that 54% of patients achieved a complete response